Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer1

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer1

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EGFR) family signaling are drivers of tumorigenesis in pancreatic ductal adenocarcinoma (PDAC). Previous studies have demonstrated that combinatorial treatment of PDAC xenografts with the mitogen-activa...

Full description

Bibliographic Details
Main Authors: Lindberg, James M., Newhook, Timothy E., Adair, Sara J., Walters, Dustin M., Kim, Alison J., Stelow, Edward B., Parsons, J. Thomas, Bauer, Todd W.
Format: Online
Language:English
Published: Neoplasia Press 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198828/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198828/

Similar Items